Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008674 | 0.94 | MAPT (0.66) | KMT2AMEN1ALDH1A1CYP2C9NAMPT | |
| SCHEMBL4004972 | 0.88 | MEN1 (0.61) | KMT2AMEN1ALDH1A1CYP2C9NAMPT | |
| SCHEMBL3851498 | 0.87 | KMT2A (0.86) | KMT2AMEN1ALDH1A1CYP2C9PKM | |
| SCHEMBL4005992 | 0.87 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CYP2C9NAMPT | |
| SCHEMBL4009437 | 0.83 | THRB (0.68) | KMT2AMEN1ALDH1A1CYP2C9PKM | |
| SCHEMBL4006225 | 0.83 | MAPT (0.79) | KMT2AMEN1ALDH1A1CYP2C9PKM | |
| SCHEMBL3851560 | 0.81 | MEN1 (0.80) | KMT2AMEN1ALDH1A1CYP2C9PKM | |
| SCHEMBL4014284 | 0.80 | NAMPT (0.59) | KMT2AMEN1ALDH1A1NAMPTMAPT | |
| SCHEMBL13796474 | 0.79 | ALDH1A1 (0.64) | KMT2AMEN1ALDH1A1CYP2C9PKM | |
| SCHEMBL3853060 | 0.78 | ALDH1A1 (1.00) | KMT2AMEN1ALDH1A1CYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306133-A1 | New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 | ACACA, ACACB, ACAT1 | KMT2A 1754/4885MEN1 4443/4885ALDH1A1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.